share_log

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary

2022 年 9 月 12 日的重要生物技术催化剂——最后一天摘要
Benzinga Real-time News ·  2022/09/12 18:32
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics' (NASDAQ:MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC). Mersana shares traded as high as 1.79 percent, in a range of $7.48 to $7.94 on day volume of 1.34 million shares, closed regular trading session at $7.48. The company shares traded at $7.40, down 1.07 percent in the after-hours trading session.
美国食品和药物管理局已批准默萨纳治疗公司(纳斯达克代码:MRSN)的主要候选药物XMT-1660用于治疗晚期或转移性三阴性乳腺癌(TNBC)的成年患者。Mersana股价一度高达1.79%,在7.48美元至7.94美元的区间内,当日成交量为134万股,常规交易时段收盘报7.48美元。该公司股价为7.40美元,在盘后交易中下跌1.07%。
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals' (NASDAQ:ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome...
美国食品和药物管理局已经接受了阿卡迪亚制药公司(纳斯达克...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发